-
-
-
-
-
-
-
Truist Securities Starts Agios Pharma (AGIO) at Buy
-
-
-
-
-
-
-
Agios' PYRUKYND receives positive European opinion for thalassemia
-
-
-
-
-
-
-
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Lowered to $71 at Scotiabank
-
-
-
-
-
-
-
FDA Accepts Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $44 at RBC Capital
-
-
-
-
-
-
-
Agios Pharma (AGIO) Announces FDA Acceptance of sNDA for TIBSOVO for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy
-
15,546 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

